Goodpasture Syndrome (Anti-GBM Disease)

Goodpasture syndrome is a rare autoimmune disease caused by autoantibodies directed against the alpha-3 chain of type IV collagen in the glomerular and alveolar basement membranes, producing a rapidly progressive pulmonary-renal syndrome of diffuse alveolar hemorrhage and crescentic glomerulonephritis that can cause fatal respiratory and renal failure within days if not recognized and treated immediately with plasmapheresis and immunosuppression.

Table of Contents

  1. Autoimmune Mechanism: Anti-GBM Antibodies
  2. Epidemiology and Associations
  3. Clinical Presentation: Pulmonary and Renal
  4. Diagnosis: Serology, Biopsy, and BAL
  5. Treatment: Plasmapheresis and Immunosuppression
  6. Monitoring and Relapse
  7. Differential Diagnosis: Pulmonary-Renal Syndromes
  8. References & Research
  9. PubMed Research Papers
  10. Featured Videos

Autoimmune Mechanism: Anti-GBM Antibodies

Goodpasture syndrome is caused by IgG autoantibodies (primarily IgG1 and IgG3 subclasses) that target a specific 36-amino-acid epitope (EA and EB epitopes) on the non-collagenous domain 1 (NC1) of the alpha-3 chain of type IV collagen — written as α3(IV)NC1. Type IV collagen is a structural scaffold protein found in basement membranes throughout the body, but the alpha-3 chain is highly enriched in two locations: the glomerular basement membrane (GBM) of kidney nephrons and the alveolar basement membrane of the lung. This restricted distribution explains why Goodpasture syndrome produces disease in the kidney and lung almost exclusively, despite circulating antibodies.

The pathogenic sequence: circulating anti-GBM IgG binds to the alpha-3(IV)NC1 target in the GBM → complement activation (C3, C5b-9 membrane attack complex) → neutrophil and monocyte recruitment → direct cytotoxic injury to the glomerular capillary wall → rupture of the glomerular basement membrane → fibrin and cellular exudate flood Bowman's space → crescent formation (proliferating parietal epithelial cells fill the urinary space) → rapidly progressive glomerulonephritis (RPGN) with loss of renal function in days to weeks. In the lung, the same antibody binds to alveolar basement membrane → complement activation → disruption of the alveolocapillary barrier → blood floods into alveoli → diffuse alveolar hemorrhage (DAH). The lung is affected in approximately 60–75% of anti-GBM disease; the remaining 25–40% have renal disease alone.

Importantly, the alpha-3(IV)NC1 epitope is normally "cryptic" — buried within the quaternary structure of the type IV collagen hexamer and not accessible to circulating B cells or antibodies under normal circumstances. For anti-GBM disease to develop, the basement membrane structure must first be disrupted, exposing this epitope. This explains why lung injury from cigarette smoke, hydrocarbon inhalation, cocaine, or pulmonary infection typically precedes the onset of pulmonary hemorrhage in Goodpasture syndrome — the initial injury disrupts the alveolar basement membrane and exposes the cryptic antigen, triggering the autoimmune response. In contrast, the GBM may be rendered susceptible by prior infection (post-streptococcal, influenza, CMV).

Back to Table of Contents

Epidemiology and Associations

Goodpasture syndrome is rare: estimated incidence of 0.5–1.8 per million per year in the US and Europe, with approximately 1–2 new cases per million per year in most cohorts. Annual case numbers are in the hundreds in the US. Despite its rarity, Goodpasture syndrome is a medical emergency because of its potential to destroy renal function permanently within days.

Age distribution is bimodal: a first peak in young men (20–30 years) — in whom pulmonary hemorrhage dominates the presentation — and a second peak in older patients (60–75 years) — in whom renal involvement predominates and pulmonary hemorrhage is less common. The male predominance in the young peak is striking; the sex ratio equalizes in the older peak.

Genetic associations: HLA-DR15 (formerly DR2) — specifically HLA-DRB1*15:01 — is present in 80–85% of patients with Goodpasture syndrome, compared to 25–30% of the general population. HLA-DRB1*03:01 is also associated. In contrast, HLA-DRB1*07:01 is protective — individuals with this allele almost never develop anti-GBM disease. The HLA-DR15 association suggests that specific HLA class II molecules present the alpha-3(IV)NC1 peptide to T helper cells and initiate the pathogenic autoimmune response.

Environmental triggers: cigarette smoking is the single strongest environmental trigger for pulmonary hemorrhage in anti-GBM disease — virtually all young men who present with DAH are smokers or have been exposed to lung irritants. Cocaine inhalation, organic solvents, hydrocarbons, metallic dust inhalation, and respiratory infections (especially influenza, reported in several epidemics) can also precipitate DAH. Renal triggers include urinary tract infection and ureteral obstruction. Lithium, penicillamine, and hydralazine have been reported in association with anti-GBM disease in small numbers of cases.

ANCA association: approximately 20–40% of patients with anti-GBM disease also have circulating ANCA (anti-neutrophil cytoplasmic antibodies), most commonly MPO-ANCA (p-ANCA). This "double-positive" pattern (anti-GBM + ANCA) is associated with more severe renal disease at presentation but paradoxically better renal recovery than anti-GBM alone — possibly because ANCA-associated disease tends to have more pauci-immune features alongside the anti-GBM lesion. Double-positive patients may also be more likely to relapse than anti-GBM-alone patients.

Back to Table of Contents

Clinical Presentation: Pulmonary and Renal

The classic Goodpasture syndrome triad is: (1) diffuse alveolar hemorrhage (DAH); (2) rapidly progressive glomerulonephritis (RPGN); and (3) positive anti-GBM antibodies. The presentation is abrupt and terrifying — a previously healthy person develops sudden-onset massive hemoptysis, severe dyspnea, and rapid deterioration in hours to days. However, the presentation can be insidious, with only isolated hematuria or dyspnea as the initial complaint.

Pulmonary manifestations: hemoptysis ranges from mild blood-streaking to massive life-threatening hemorrhage. DAH can also occur without frank hemoptysis — the blood diffuses into alveolar airspaces without reaching the airways large enough to produce visible expectoration. Symptoms include dyspnea, cough, chest tightness, and hypoxemia. Chest X-ray or CT shows bilateral patchy or confluent airspace opacities (blood in alveoli) that are most prominent in the perihilar regions and lower lobes but can be diffuse. The opacities can clear remarkably quickly (24–48 hours) if bleeding stops and hemoglobin is reabsorbed — a radiographic "migration" pattern that is nearly specific for DAH compared to other airspace processes.

Renal manifestations: hematuria (dysmorphic red blood cells and red blood cell casts on urine microscopy — the hallmark of glomerulonephritis and an indispensable early sign), proteinuria (usually non-nephrotic), and rapidly rising creatinine. RPGN can bring a patient from normal creatinine to dialysis dependence in days to weeks. Hypertension and edema occur as renal function deteriorates. Oliguria or anuria indicate severe crescentic GN requiring immediate aggressive therapy.

Clinical phenotypes: (1) Pulmonary-renal syndrome — the classic presentation with both DAH and RPGN (60% of cases). (2) Renal-limited disease — RPGN without pulmonary hemorrhage (25–40%); often older patients; the "silent" form that can reach renal failure before diagnosis. (3) Pulmonary-limited disease — DAH without apparent renal involvement (rare); monitor carefully for renal involvement over time. Constitutional symptoms — fever, malaise, weight loss — are common and can be confused with systemic vasculitis.

Back to Table of Contents

Diagnosis: Serology, Biopsy, and BAL

The diagnosis of Goodpasture syndrome requires demonstrating anti-GBM antibodies in serum and/or typical linear IgG deposition on renal or lung biopsy. Diagnostic workup should proceed in parallel with empiric treatment — do NOT wait for biopsy results before starting plasmapheresis and immunosuppression in an acutely deteriorating patient.

Serum anti-GBM antibody testing (ELISA): the primary diagnostic test. Sensitivity 85–95%, specificity >95% for anti-GBM disease. IgG anti-GBM antibodies against the alpha-3(IV)NC1 antigen. Titer roughly correlates with disease activity and can be used to monitor response to plasmapheresis. ELISA should be ordered STAT — results typically available within 24–48 hours at most centers. False negatives can occur early in the disease or in patients with very low antibody titers.

Renal biopsy: the gold standard for diagnosis and for assessing the degree of crescentic injury — which determines reversibility and prognosis. Light microscopy: crescentic glomerulonephritis with necrosis; crescents in >50% of glomeruli in severe disease. Immunofluorescence (IF): linear IgG deposition along the GBM — the pathognomonic finding. This linear pattern distinguishes anti-GBM disease from immune complex GN (granular/lumpy-bumpy IF pattern in lupus, IgA nephropathy, post-streptococcal GN) and from ANCA-vasculitis (pauci-immune — scant or absent IF staining).

ANCA testing (ANCAs, anti-MPO, anti-PR3): ordered simultaneously with anti-GBM antibodies to identify double-positive patients and exclude isolated ANCA-vasculitis (which has different prognosis and relapse pattern).

BAL (bronchoalveolar lavage) for DAH confirmation: hemorrhagic BAL with progressively bloody returns across sequential aliquots; hemosiderin-laden macrophages (>20% on iron stain = evidence of prior bleeding). BAL also excludes infection as the cause of hemoptysis/airspace disease.

HRCT chest: bilateral ground glass opacities (fresh blood) and consolidation; subpleural sparing in some cases; may be predominantly perihilar.

Back to Table of Contents

Treatment: Plasmapheresis and Immunosuppression

Goodpasture syndrome is a rare emergency where hours matter. The therapeutic principle is: (1) REMOVE the pathogenic anti-GBM antibodies with plasmapheresis; and (2) SUPPRESS new antibody production with high-dose immunosuppression; and (3) REPLACE plasma proteins lost during plasmapheresis.

Plasmapheresis (therapeutic plasma exchange, TPE): the cornerstone of treatment. Each plasmapheresis session exchanges 4 liters of plasma (approximately 1 plasma volume) against human albumin or fresh frozen plasma, removing circulating anti-GBM IgG. Standard course: daily plasmapheresis for 14 days or until anti-GBM antibodies are undetectable, then tapering to alternate-day sessions. Anti-GBM titers typically become undetectable by 2–3 weeks of daily plasmapheresis. FFP replacement is used if the patient has significant coagulopathy or active pulmonary hemorrhage. Vascular access: large-bore central venous catheter (dialysis-type, dual-lumen) is required; peripheral access is inadequate.

Immunosuppression: high-dose intravenous methylprednisolone (500–1000 mg/day IV for 3 days = "pulse steroids") followed by oral prednisone 1 mg/kg/day (maximum 60–80 mg/day) tapering over 6–9 months. Cyclophosphamide (oral or IV) is added to eliminate anti-GBM-producing B cells and plasma cells: oral cyclophosphamide 2 mg/kg/day for 3 months, or IV pulse cyclophosphamide (monthly). Dose reduction in renal impairment is essential (cyclophosphamide is renally cleared and its toxic metabolite acrolein accumulates in renal failure). Rituximab (anti-CD20 monoclonal antibody) may be used as an alternative or adjunct to cyclophosphamide, with emerging evidence supporting B-cell depletion as a therapeutic strategy.

Treatment outcomes: if treated aggressively before significant renal damage (creatinine <5.7 mg/dL, <50% crescents on biopsy), renal recovery is possible in 50–80% of patients. If oliguria or creatinine >5.7 mg/dL is already present at diagnosis, renal recovery is unlikely even with aggressive therapy — most patients who reach this threshold ultimately require renal replacement therapy (dialysis, then transplant). Pulmonary hemorrhage responds more rapidly than renal disease — DAH often resolves within 2–4 weeks with plasmapheresis.

Indications for proceeding despite severe renal failure: plasmapheresis and immunosuppression should still be given even in dialysis-dependent patients, because they may reduce pulmonary hemorrhage severity and some renal recovery is occasionally possible even from a severe baseline.

Back to Table of Contents

Monitoring and Relapse

Anti-GBM antibody titers: monitored every 2–4 weeks during treatment. Persistent antibody elevation despite plasmapheresis indicates inadequate clearance and may necessitate intensified sessions. Antibody negativity typically occurs by 3–8 weeks. After negativity is achieved, monitoring monthly for several months confirms sustained remission.

Relapse: anti-GBM disease is generally a monophasic illness — unlike ANCA vasculitis, relapse is uncommon (estimated 2–3%) because B-cell tolerance to the alpha-3(IV)NC1 epitope is typically re-established after the antibody-producing clones are eliminated. Relapse is more common in double-positive (anti-GBM + ANCA) patients. Re-exposure to cigarette smoke or pulmonary injurious agents can precipitate relapse; strict smoking cessation is mandatory.

Renal replacement therapy: patients who progress to end-stage renal disease (ESRD) require dialysis. Renal transplantation is safe after anti-GBM antibodies have been undetectable for at least 6–12 months (to prevent recurrence in the transplanted kidney). Recurrence in transplanted kidneys is rare when antibody negativity is confirmed pre-transplant.

Post-treatment monitoring: PFTs (spirometry, DLCO), repeat HRCT if pulmonary symptoms recur, urinalysis and serum creatinine indefinitely in those with any renal involvement. Long-term pulmonary sequelae after DAH in Goodpasture syndrome are usually mild; significant fibrosis is rare with a single episode.

Back to Table of Contents

Differential Diagnosis: Pulmonary-Renal Syndromes

Goodpasture syndrome must be distinguished from other causes of pulmonary-renal syndrome, particularly because the treatments overlap but differ in important details.

Granulomatosis with Polyangiitis (GPA/Wegener's): ANCA-positive (predominantly PR3-ANCA/c-ANCA); upper airway involvement (sinusitis, nasal destruction, tracheal stenosis); granulomatous inflammation on biopsy (absent in Goodpasture); pauci-immune GN (no linear IgG on IF). GPA can also cause DAH and RPGN. ANCA testing and biopsy distinguish GPA from Goodpasture.

Microscopic Polyangiitis (MPA): ANCA-positive (predominantly MPO-ANCA/p-ANCA); systemic small vessel vasculitis; no granulomas; pauci-immune GN; DAH less common than in GPA but occurs. Distinguishable from Goodpasture by ANCA pattern and pauci-immune IF.

Systemic Lupus Erythematosus (SLE): can cause lupus nephritis (class III-IV) with RPGN and DAH (pulmonary hemorrhage in SLE is rare but carries high mortality); ANA positive; anti-dsDNA positive; granular/mesangial immune complex deposition on IF (not linear); complement consumption (low C3, C4); other lupus features (rash, serositis, cytopenias).

Eosinophilic Granulomatosis with Polyangiitis (EGPA/Churg-Strauss): eosinophilia; asthma; neuropathy; p-ANCA positive in subset; rarely causes DAH or RPGN — more commonly causes eosinophilic pneumonia and myocarditis; eosinophil-predominant tissue infiltration.

IgA Nephropathy with pulmonary hemorrhage: rare combination; mesangial IgA deposition on biopsy (not linear IgG); less acute than Goodpasture.

Key distinguishing tests: anti-GBM antibody (linear GBM IF = Goodpasture), ANCA (PR3/MPO), ANA/anti-dsDNA, complement levels, ANCA vasculitis biopsy (pauci-immune), eosinophil count. The pulmonary-renal syndrome differential should be worked up simultaneously and aggressively because multiple entities can coexist.

Back to Table of Contents

References & Research

  1. Hellmark T, Segelmark M. Diagnosis and classification of Goodpasture's disease (anti-GBM). J Autoimmun. 2014;48-49:108-112. PMID 24524923
  2. McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol. 2017;12(7):1162-1172. PMID 28515156
  3. Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003;64(4):1535-1550. PMID 12969174
  4. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63(3):1164-1177. PMID 12631105
  5. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033-1042. PMID 11388816
  6. Huart A, Josse AG, Chauveau D, et al. Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Nephrology. J Autoimmun. 2016;73:53-61. PMID 27262985
  7. Segelmark M, Hellmark T. Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant. 2021;36(4):599-606. PMID 32658984
  8. Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med. 2010;363(4):343-354. PMID 20660401
  9. Canney M, O'Hara PV, McEvoy CM, et al. Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol. 2016;11(8):1392-1399. PMID 27340285
  10. Olson SW, Arbogast CB, Baker TP, et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol. 2011;22(10):1946-1952. PMID 21903990
  11. Herody M, Bobrie G, Gouarin C, Grünfeld JP, Noel LH. Anti-GBM disease: predictive value of clinical, histological and serological data. Clin Nephrol. 1993;40(5):249-255. PMID 8281711
  12. Lazor R, Bigay-Gamé L, Cottin V, et al. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore). 2007;86(3):181-193. PMID 17519713

Back to Table of Contents

PubMed Research Papers

  1. Goodpasture syndrome anti-GBM antibody
  2. Anti-GBM disease treatment plasmapheresis
  3. Diffuse alveolar hemorrhage pulmonary-renal syndrome
  4. Crescentic glomerulonephritis rapidly progressive
  5. Alpha-3 type IV collagen autoimmune kidney
  6. Anti-GBM ANCA double-positive vasculitis
  7. HLA-DR15 Goodpasture genetic susceptibility
  8. Plasmapheresis plasma exchange autoimmune kidney disease
  9. Pulmonary hemorrhage smoking autoimmune lung
  10. Anti-GBM renal transplant recurrence outcome

Back to Table of Contents

Connections

Back to Table of Contents